EI
LXEO icon

Ethic Inc’s Lexeo Therapeutics LXEO Stock Holding History

Ethic Inc’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,132
Closed -$63.9K – 1396
2026
Q1 		$63.9K Sell
11,132
-317
-3% -$2.25K ﹤0.01% 1212
2025
Q4 		$114K Buy
11,449
+130
+1% +$1.19K ﹤0.01% 1170
2025
Q3 		$75.2K Buy
11,319
+593
+6% +$2.87K ﹤0.01% 1163
2025
Q2 		$44.2K Buy
+10,726
New +$35.3K ﹤0.01% 1193

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Ethic Inc's LXEO Position: Q2 2026 in Review

Ethic Inc sold out of Lexeo Therapeutics (LXEO) in Q2 2026, closing a stake of 11,132 shares — an estimated $63.9K sold.

Ethic Inc first reported a position in LXEO in Q2 2025 and held it in 4 quarters. The position peaked at $114K in Q4 2025. 141 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Ethic Inc reported no remaining Lexeo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ethic Inc sold 11,132 Lexeo Therapeutics shares in Q2 2026, an estimated $63.9K.
  • Ethic Inc first reported a position in Lexeo Therapeutics in Q2 2025 and held it in 4 quarters.
  • Ethic Inc's Lexeo Therapeutics position peaked at $114K in Q4 2025.
  • 141 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.